Bristol Myers Secures FDA Nod For Opdivo Plus Chemo For Untreated Hodgkin Lymphoma

Benzinga01:57

• Bristol-Myers Squibb shares are experiencing downward pressure. Why is BMY stock retreating? Hodgkin lymphoma (HL) is a cancer in which multinucleated Reed–Sternberg cells (RS cells) are present in ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621755198?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/20/Rueil-malmaison--France---August-13--202.jpeg?optimize=medium&dpr=2&auto=webp&width=630","is_english":true,"pubTime":"2026-03-21 01:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621755198","market":"nz","top_or_hot":-1,"title":"Bristol Myers Secures FDA Nod For Opdivo Plus Chemo For Untreated Hodgkin Lymphoma","media":"Benzinga","content":"<div>\n<p>• Bristol-Myers Squibb shares are experiencing downward pressure. Why is BMY stock retreating?\nHodgkin lymphoma (HL) is a cancer in which multinucleated Reed–Sternberg cells (RS cells) are present in ...</p>\n\n<a href=\"https://www.benzinga.com/news/fda/26/03/51387020/bristol-myers-secures-fda-nod-for-opdivo-plus-chemo-for-untreated-hodgkin-lymphoma\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol Myers Secures FDA Nod For Opdivo Plus Chemo For Untreated Hodgkin Lymphoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol Myers Secures FDA Nod For Opdivo Plus Chemo For Untreated Hodgkin Lymphoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-21 01:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/fda/26/03/51387020/bristol-myers-secures-fda-nod-for-opdivo-plus-chemo-for-untreated-hodgkin-lymphoma><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>• Bristol-Myers Squibb shares are experiencing downward pressure. Why is BMY stock retreating?\nHodgkin lymphoma (HL) is a cancer in which multinucleated Reed–Sternberg cells (RS cells) are present in ...</p>\n\n<a href=\"https://www.benzinga.com/news/fda/26/03/51387020/bristol-myers-secures-fda-nod-for-opdivo-plus-chemo-for-untreated-hodgkin-lymphoma\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1032466523.USD","symbol_name":"高盛全球多资产收益组合Acc","start_time":0,"source_url":"https://www.benzinga.com/news/fda/26/03/51387020/bristol-myers-secures-fda-nod-for-opdivo-plus-chemo-for-untreated-hodgkin-lymphoma","article_id":"2621755198","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/20/Rueil-malmaison--France---August-13--202.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/fda/26/03/51387020/bristol-myers-secures-fda-nod-for-opdivo-plus-chemo-for-untreated-hodgkin-lymphoma","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2621755198","pubTimestamp":1774029420,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Bristol-Myers Squibb shares are experiencing downward pressure. Why is BMY stock retreating?Hodgkin lymphoma  is a cancer in which multinucleated Reed–Sternberg cells  are present in the lymph nodes.Nivolumab received accelerated approval for these indications in 2016 and 2017, respectively.Efficacy of nivolumab in combination with AVD was evaluated in Study CA209-8UT. A total of 994 patients were randomized.The study demonstrated superiority of progression-free survival  in the nivolumab plus AVD arm, with a hazard ratio of 0.42.The median PFS was not reached in either arm, after a median follow-up of 13.7 months.After a median follow-up of 36.7 months, there were 1.8% deaths in the nivolumab plus AVD arm and 3.4% in the brentuximab vedotin plus AVD arm.In 2025, Opdivo generated revenues of $5.9 billion.Earlier in March, the FDA approved Bristol Myers’ oral drug Sotyktu to treat adults with active psoriatic arthritis.BMY Stock Price Activity:Bristol Myers Squibb shares were down1.33%a","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1032466523.USD":"高盛全球多资产收益组合Acc","LU0882574055.USD":"富达全球健康医疗A ACC","BK4570":"地缘局势概念股","LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","BK4585":"ETF&股票定投概念","BMY":"施贵宝","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0345780521.USD":"NINETY ONE GSF GLOBAL GOLD \"A\" (USD) INC","HL":"赫克拉矿业","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0237698245.USD":"富达环球地产基金A","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LABU":"三倍做多标普生物-Direxion","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","BK4126":"金属与玻璃容器","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0345780281.USD":"NINETY ONE GSF GLOBAL GOLD \"A\"  ACC","BK4588":"碎股","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","MYE":"Myers Industries Inc","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","BK4007":"制药","BK4211":"区域性银行","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","PFS":"Provident Financial Services Inc","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","BK4210":"白银","BK4581":"高盛持仓"},"translate_title":"百时美施贵宝(Bristol Myers)获得FDA批准Opdivo加化疗治疗未经治疗的霍奇金淋巴瘤","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYE":1.5,"LABU":1.5,"PFS":1,"HL":1,"BMY":0.79},"content_text":"• Bristol-Myers Squibb shares are experiencing downward pressure. Why is BMY stock retreating?\nHodgkin lymphoma (HL) is a cancer in which multinucleated Reed–Sternberg cells (RS cells) are present in the lymph nodes.\nNivolumab received accelerated approval for these indications in 2016 and 2017, respectively.\nEfficacy of nivolumab in combination with AVD was evaluated in Study CA209-8UT. A total of 994 patients were randomized.\nThe study demonstrated superiority of progression-free survival (PFS) in the nivolumab plus AVD arm, with a hazard ratio of 0.42.\nThe median PFS was not reached in either arm, after a median follow-up of 13.7 months. \nAfter a median follow-up of 36.7 months, there were 1.8% deaths in the nivolumab plus AVD arm and 3.4% in the brentuximab vedotin plus AVD arm.\nIn 2025, Opdivo generated revenues of $5.9 billion.\nEarlier in March, the FDA approved Bristol Myers’ oral drug Sotyktu to treat adults with active psoriatic arthritis.\nBMY Stock Price Activity: Bristol Myers Squibb shares were down 1.33% at $57.34 at the time of publication on Friday, according to Benzinga Pro data.\nImage via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621755198","isCrawlerRequest":true}